Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25919978 | 0.85 | DRD2 (0.40) | DRD2DRD3NPC1RAB9AGRIN1 | |
| SCHEMBL25317121 | 0.85 | DRD2 (0.40) | DRD2DRD3NPC1RAB9AGRIN1 | |
| SCHEMBL26022163 | 0.81 | PDK2 (0.43) | PDK2EPHX2TDP1MAPK1MMP3 | |
| SCHEMBL26022199 | 0.77 | PDK2 (0.40) | TRPV1PDK2EPHX2TDP1MAPK1 | |
| SCHEMBL25902791 | 0.75 | PDK2 (0.41) | PDK2EPHX2TDP1MAPK1MMP3 | |
| SCHEMBL10352864 | 0.74 | TDP1 (0.54) | PDK2EPHX2TDP1MAPK1RAB9A | |
| SCHEMBL25902244 | 0.74 | NPC1 (0.65) | EPHX2TDP1DRD3MAPK1MMP3 | |
| SCHEMBL26022185 | 0.73 | PDK2 (0.42) | PDK2EPHX2TDP1MAPK1MMP3 | |
| SCHEMBL24869535 | 0.73 | L3MBTL1 (0.42) | TRPV1 | |
| SCHEMBL25788203 | 0.72 | THRA (0.49) | PDK2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | TRPV1 4818/4885PDK2 3901/4885EPHX2 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.